T. Rowe Price Associates’s Metagenomi Therapeutics MGX Stock Holding History

T. Rowe Price Associates’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,755	Closed	-$15K	–	3164
2025 Q1	$15K	Hold	10,755	–	–	﹤0.01%	3018
2024 Q4	$39K	Buy	+10,755	New	+$25.9K	﹤0.01%	2964

Other funds holding MGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SVGI

Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates's MGX Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Metagenomi Therapeutics (MGX) in Q2 2025, closing a stake of 10,755 shares — an estimated $15K sold.

T. Rowe Price Associates first reported a position in MGX in Q4 2024 and held it in 2 quarters. The position peaked at $39K in Q4 2024. 69 funds tracked by Wall St. Rank hold MGX as of Q2 2025.

T. Rowe Price Associates reported no remaining Metagenomi Therapeutics position as of Q2 2025 after selling out during the quarter.
T. Rowe Price Associates sold 10,755 Metagenomi Therapeutics shares in Q2 2025, an estimated $15K.
T. Rowe Price Associates first reported a position in Metagenomi Therapeutics in Q4 2024 and held it in 2 quarters.
T. Rowe Price Associates's Metagenomi Therapeutics position peaked at $39K in Q4 2024.
69 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.